Arcus Biosciences (NYSE: RCUS) reported Q4 EPS of ($0.89), $0.21 better than the analyst estimate of ($1.10). Revenue for the quarter came in at $33 million versus the consensus estimate of $35.71 million.

For earnings history and earnings-related data on Arcus Biosciences (RCUS) click here.